Market Overview

Navidea Biopharmaceuticals Announces Presentation at the Radiological Society of North America (RSNA) 104th Scientific Assembly and Annual Meeting 2018

Share:

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) ("Navidea" or the
"Company"), a company focused on the development of precision
immunodiagnostic agents and immunotherapeutics, today announced that Dr.
David Ralph, Director of Drug Development and IP Manager of Navidea,
will be presenting at the RSNA 104th Scientific Assembly and
Annual Meeting, which is taking place November 25-30, 2018 in Chicago,
IL.

The oral presentation will highlight an abstract evaluated and selected
through a competitive, blind peer-review process. The presentation will
focus on recent imaging results obtained from Kaposi Sarcoma patients
who have received 99mTc-tilmanocept by either a subcutaneous or an
intravenous route of administration.

Oral Presentation Details
Presentation Title: Planar and
SPECT/CT Imaging in Human Immunodeficiency Virus (HIV) Subjects
Diagnosed with Kaposi Sarcoma (KS) using Intravenous 99mTc-tilmanocept

Abstract:
SSK19-06
When: Wednesday, November 28 at 11:20am CT
Where:
McCormick Place, Chicago, IL
Room: S504AB

RSNA 2018 annual meeting provides a hands on experience with
cutting-edge tech, including artificial intelligence, 3D printing and
virtual reality. Sessions cover the latest research and provides a
platform to enhance skills and network. Over 70,000 people will attend
this annual meeting.

More details on the annual meeting, including the full agenda can be
found at https://www.rsna.org/Annual-Meeting.

About Navidea

Navidea Biopharmaceuticals, Inc. (NYSE:NAVB) is a
biopharmaceutical company focused on the development of precision
immunodiagnostic agents and immunotherapeutics. Navidea is developing
multiple precision-targeted products based on its Manocept™ platform to
enhance patient care by identifying the sites and pathways of disease
and enable better diagnostic accuracy, clinical decision-making, and
targeted treatment. Navidea's Manocept platform is predicated on the
ability to specifically target the CD206 mannose receptor expressed on
activated macrophages. The Manocept platform serves as the molecular
backbone of Tc99m tilmanocept, the first product developed and
commercialized by Navidea based on the platform. The development
activities of the Manocept immunotherapeutic platform are being
conducted by Navidea in conjunction with its subsidiary, Macrophage
Therapeutics, Inc. Navidea's strategy is to deliver superior growth and
shareholder return by bringing to market novel products and advancing
the Company's pipeline through global partnering and commercialization
efforts.

For more information, please visit www.navidea.com.

Forward-Looking Statements

This release and any oral statements made with respect to the
information contained in this release contains forward-looking
statements within the meaning of Section 27A of the Securities Act of
1933, as amended, and Section 21E of the Securities Exchange Act of
1934, as amended. We have based these forward-looking statements largely
on our current expectations and projections about future events and
financial trends affecting the financial condition of our business.
These forward-looking statements are subject to a number of risks,
uncertainties and assumptions, including, among other things: any future
actions by Platinum-Montaur; general economic and business conditions,
both nationally and in our markets; our history of losses and
uncertainty of future profitability; the final outcome of the CRG
litigation in Texas and Ohio; our ability to successfully complete
research and further development of our drug candidates; the timing,
cost and uncertainty of obtaining regulatory approvals of our drug
candidates; our ability to successfully commercialize our drug
candidates; our expectations and estimates concerning future financial
performance, financing plans and the impact of competition; our ability
to raise capital sufficient to fund our development and
commercialization programs; our ability to implement our growth
strategy; anticipated trends in our business; advances in technologies;
our ability to comply with the NYSE American continued listing
standards; and other risk factors detailed in our most recent Annual
Report on Form 10-K and other SEC filings. You are urged to carefully
review and consider the disclosures found in our SEC filings, which are
available at www.sec.gov or
at http://ir.navidea.com.

Investors are urged to consider statements that include the words
"will," "may," "could," "should," "plan," "continue," "designed,"
"goal," "forecast," "future," "believe," "intend," "expect,"
"anticipate," "estimate," "project," and similar expressions, as well as
the negatives of those words or other comparable words, to be uncertain
forward-looking statements.

You are cautioned not to place undue reliance on any forward-looking
statements, any of which could turn out to be incorrect. We undertake no
obligation to update publicly or revise any forward-looking statements,
whether as a result of new information, future events or otherwise after
the date of this report. In light of these risks and uncertainties, the
forward-looking events and circumstances discussed in this report may
not occur and actual results could differ materially from those
anticipated or implied in the forward-looking statements.

View Comments and Join the Discussion!
 
Lightning Fast
Market News Service
$199 Free 14 Day Trial